Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study-Reference-Cited by-同舟云学术

Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study

Published:2024-08-04 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Blum David¹²,Cailliau Emeline³,Béhal Hélène³,Vidal Jean‐Sébastien⁴,Delaby Constance⁵⁶,Buée Luc¹²,Allinquant Bernadette⁷,Gabelle Audrey⁸,Bombois Stéphanie²⁹,Lehmann Sylvain⁵,Schraen‐Maschke Susanna¹²,Hanon Olivier⁴,

Affiliation:

1. University of Lille, Inserm, CHU Lille UMR‐S1172 Lille Neuroscience & Cognition (LilNCog) Lille France

2. Alzheimer and Tauopathies LabEx DISTALZ Lille France

3. Department of Biostatistics CHU Lille Lille France

4. Université Paris Cité INSERM U1144, GHU APHP Centre Hopital Broca, Memory Resource and Research Centre de Paris‐Broca‐Ile de France Paris France

5. Laboratoire et Plateforme de Protéomique Clinique Université de Montpellier INM INSERM, IRMB CHU de Montpellier, 80 av Fliche Montpellier France

6. Sant Pau Memory Unit Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain

7. Université Paris Cité Institute of Psychiatry and Neuroscience, Inserm, UMR‐S 1266 Paris France

8. Université de Montpellier CHU Montpellier Memory Research and Resources Center Department of Neurology, Inserm INM NeuroPEPs Team Excellence Center of Neurodegenerative Disorders Montpellier France

9. Assistance Publique‐Hôpitaux de Paris (AP‐HP) Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié‐Salpêtrière Paris France

Abstract

AbstractINTRODUCTIONWe investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients.METHODSMCI (N = 147) and AD (N = 116) patients of the Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p‐tau181, amyloid beta 1‐42 [Aβ1‐42], Aβ1‐40) were analyzed using logistic and analysis of covariance models.RESULTSAdjusted on Apolipoprotein E (APOE ε4), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p = 0.023) and lower CSF Aβ1‐42 (p = 0.047), Aβ1‐42/Aβ1‐40 (p = 0.040), and Aβ1‐42/p‐tau181 (p = 0.020) in the whole cohort.DISCUSSIONData support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.Highlights

We studied the impact of caffeine consumption in the BALTAZAR cohort.

Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients.

Caffeine intake is associated with CSF biomarkers in AD patients.

Publisher

Wiley

Reference73 articles.

1. The Cellular Phase of Alzheimer’s Disease

2. Epidemiology of Alzheimer disease

3. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use;Fredholm BB;Pharmacol Rev,1999

4. Association of Coffee Drinking with Total and Cause-Specific Mortality